The effect of peritoneal rest in combination therapy of peritoneal dialysis and hemodialysis: using the cultured human peritoneal mesothelial cell model
- PMID: 16094518
- DOI: 10.1007/s10047-005-0290-3
The effect of peritoneal rest in combination therapy of peritoneal dialysis and hemodialysis: using the cultured human peritoneal mesothelial cell model
Abstract
The effects of peritoneal rest for 24 h during peritoneal dialysis and hemodialysis combination therapy were investigated using cultured human peritoneal mesothelial cell (HPMC) models. Cell activity was investigated by 3-[4,5-dimethylthiazol-2-yl]-2, 5-diphenylterazolium bromide (MTT) assay after exposing HPMCs to peritoneal dialysis fluids (PDFs) with different pH levels. The following PDFs (50 microl/well) were used for exposure durations of 30 or 240 min: acidic heat-sterilized PDFs (L-H PDF, pH 5.5) and neutral heat-sterilized PDFs (N-H PDF, pH 6.7). Control wells were exposed to M-199 Hanks medium containing 20% fetal bovine serum (FBS) for 30 or 240 min. Supernatants were then aspirated from each well and M-199 culture medium containing 20% FBS (50 microl) was added to each well to rest HPMCs for 24 h before investigation of MTT activity. The activity of HPMCs exposed to L-H PDF for 240 min decreased to approximately 20% and 15% when compared with controls (glucose concentrations of 1.36% and 3.86%, respectively; P < 0.01 versus control, Tukey-Kramer test), and to approximately 60% and 40% after exposure to N-H PDF for 240 min (glucose: 1.36% and 3.86%; P < 0.01). The activity of HPMCs exposed to L-H PDF for 240 min followed by rest was approximately 20% and 4% when compared with controls (glucose: 1.36% and 3.86%; P < 0.01) and was 93% and 96% when compared with controls after exposure to N-H PDF for 240 min followed by rest (glucose: 1.36% and 3.86%). These findings suggest that rest for 24 h after exposure to N-H PDF improves the activity of HPMCs.
Similar articles
-
Mesothelial toxicity of peritoneal dialysis fluids is related primarily to glucose degradation products, not to glucose per se.Perit Dial Int. 2003 Jul-Aug;23(4):381-90. Perit Dial Int. 2003. PMID: 12968847
-
Peritoneal dialysis with solutions low in glucose degradation products is associated with improved biocompatibility profile towards peritoneal mesothelial cells.Nephrol Dial Transplant. 2004 Apr;19(4):917-24. doi: 10.1093/ndt/gfh013. Nephrol Dial Transplant. 2004. PMID: 15031350 Clinical Trial.
-
Newly Developed Neutralized pH Icodextrin Dialysis Fluid: Nonclinical Evaluation.Artif Organs. 2016 Aug;40(8):E158-66. doi: 10.1111/aor.12783. Artif Organs. 2016. PMID: 27530675
-
Biocompatibility and buffers: effect of bicarbonate-buffered peritoneal dialysis fluids on peritoneal cell function.Kidney Int. 1998 Dec;54(6):2184-93. doi: 10.1046/j.1523-1755.1998.00178.x. Kidney Int. 1998. PMID: 9853285 Review.
-
Glucose degradation products in peritoneal dialysis: from bench to bedside.Kidney Blood Press Res. 2003;26(2):113-7. doi: 10.1159/000070993. Kidney Blood Press Res. 2003. PMID: 12771536 Review.
Cited by
-
APD or CAPD: one glove does not fit all.Int Urol Nephrol. 2021 Jun;53(6):1149-1160. doi: 10.1007/s11255-020-02678-6. Epub 2020 Oct 13. Int Urol Nephrol. 2021. PMID: 33051854 Free PMC article. Review.
-
Effects of incremental peritoneal dialysis with low glucose-degradation product neutral pH solution on clinical outcomes.Int Urol Nephrol. 2024 Sep;56(9):3123-3132. doi: 10.1007/s11255-024-04077-7. Epub 2024 May 14. Int Urol Nephrol. 2024. PMID: 38740705
-
Clinical application of computer-aided diagnostic system for harmonious introduction of complementary dialysis therapy.Open Biomed Eng J. 2008 Apr 1;2:10-6. doi: 10.2174/1874120700802010010. Open Biomed Eng J. 2008. PMID: 19662111 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical